ReviewFrontiers in oncology2026
Advances and challenges in the application of prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is the fifth most common malignant tumor worldwide and the third leading cause of cancer-related deaths, posing a serious threat to global public health. Despite notable advancements in surgical techniques, systemic chemotherapy, targeted therapy, and immunotherapy in recent years, the overall prognosis for patients with locally advanced gastric cancer (AGC) remains suboptimal, primarily due to the high propensity for local and distant metastasis. Peritoneal metastasis (PM), in particular, has become one of the most formidable clinical challenges owing to its high incidence, inherent resistance to systemic chemotherapy, and extremely poor prognosis. To address this challenge, Prophylactic Hyperthermic Intraperitoneal Chemotherapy (P-HIPEC) has emerged as a focal point of research. This therapeutic modality aims to eradicate microscopic residual tumors and free cancer cells in the abdominal cavity following radical gastrectomy, thereby effectively reducing the risk of peritoneal metastasis and improving long-term patient survival. This review systematically examines the latest research progress of P-HIPEC in the treatment of gastric cancer, provides an in-depth analysis of its mechanism of action, indications, criteria for patient and drug selection, evidence of clinical efficacy, safety controversies, and challenges in standardization. It also looks forward to future research directions in this field, with the aim of providing a valuable reference for clinical practice and academic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.